Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
The conversation humorously discusses two resilient hair strands that resist DHT, with mentions of minoxidil and finasteride as ineffective treatments. Users joke about cloning the hairs and the mystery of baldness.
The conversation discusses dissatisfaction with current hair loss treatments that mainly focus on DHT blockers like finasteride and dutasteride. Alternative treatments mentioned include RU58841, pyrilutamide, minoxidil, rosemary oil, and future possibilities like hair cloning.
Potential treatments for hair loss, including Minoxidil, finasteride, RU58841 and various upcoming pharmaceuticals, gene editing and cloning. It is suggested that a cure, if found, would be highly profitable due to the large number of people affected by hair loss globally.
A user shared their 14-year experience with hair loss treatments, primarily using finasteride, minoxidil, and Nizoral. They highlighted the effectiveness of finasteride despite some side effects and emphasized the importance of early prevention and the potential for negative selection bias in online reviews.
The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
User shared a 10-month update after a 4000-graft hair transplant, using finasteride, minoxidil, hair density shampoos, hair oils, and vitamins. Replies suggest patience as crown growth can take up to 18 months.
Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
The conversation discusses the lack of significant advancements in hair loss treatments since the introduction of finasteride 22 years ago, with many expressing frustration over the failure of new projects and skepticism about future developments. Some users mention hair transplants and other potential alternatives like Alfatradiol and Fluridil, but acknowledge finasteride's dominance in the market due to its effectiveness and affordability.
The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
The conclusion of the conversation is that the user has tried various medications and treatments for hair loss, including minoxidil, finasteride, microneedling, and nizoral shampoo, but has not seen any progress. They have decided to shave their head. Other users suggest options such as hair transplants, RU58841, hair units, and scalp micropigmentation.
Using a combination of topical minoxidil and finasteride, plus microneedling, to treat hair loss; the progress made by the original poster over 6 months; the potential for further results with longer use; and the possibility of seeking alternatives such as a hair transplant or system.
The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.
The conversation expresses frustration over the lack of progress in hair loss treatments, with specific mentions of Minoxidil, finasteride, and RU58841. Users discuss the slow development of new treatments and the potential of hair transplants.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation expresses frustration over the lack of clear evidence regarding the effectiveness and systemic impact of topical Dutasteride for hair loss treatment, despite years of discussion. People are criticized for not conducting proper research and for providing contradictory anecdotal claims.
The user has been using finasteride for 1.5 years and minoxidil for almost 3 years for hair loss, and has seen some maintenance of hair but not significant regrowth. Suggestions from others include switching to dutasteride, trying oral minoxidil, and considering microneedling or hair fibers for better appearance.
The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.
User tried Minoxidil and Finasteride for hair loss with no success and considers giving up. Others suggest continuing treatment, trying hair transplant, or embracing baldness.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.